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ABSTRACT 
Association of chronic arsenic exposure with diabetes mellitus is fairly well established, 
but the association of arsenic toxicity with glucose intolerance in pregnancy and with 
neonatal outcome have yet not been studied adequately. The present study was 
undertaken to explore the association of chronic arsenic exposure with gestational 
diabetes mellitus (GDM) and neonatal outcome in a Bangladeshi population. Under an 
observational cross-sectional design a total of 263 pregnant women (age in yrs, M±SD, 
21±3.7) residing in an arsenic affected area of Bangladesh, were subjected to a 2 sample 
OGTT at third trimester of gestation. Clinical and anthropometric measurements were 
done by standard techniques. Degree of chronic arsenic exposure was assessed by the 
level of As in the usable (drinking, cooking, washing and bathing) water at the 
respective households and total urinary arsenic level. GDM was diagnosed by WHO 
criteria and neonatal outcome was assessed using APGAR Score measured by a 
Specialist Obstetrician. Serum glucose was measured by Glucose Oxidase method and 
As level in water (WAs) was measured by ultraviolet/visible spectrophotometry. Out of 
the 263 pregnant women 73(28%) developed GDM. WAs was significantly higher in 
the GDM as compared to the Non-GDM group [WAs, µg/l, median (range), 62(34-354) 
vs 3.6(1.02-99), p<0.001]. Apger Score of the neonates from GDM mothers was 
significantly lower compared to the neonates from Non-GDM mothers [APGER Score, 
M±SD, 4.7±0.8 vs 6.4±0.7, p<0.001]. On Pearson’s correlation analysis in GDM 
subjects, both fasting and postprandial serum glucose levels were found to have a 
significant positive correlation with WAs levels (r=0.429;p=<0.001) and water arsenic 
and also significant positive correlation with water arsenic (r=0.234; p<0.001). The 
APGER Score of the neonates were found to have a significant negative correlation (r=-
0.233; p=0.041) with WAs level. Chronic arsenic exposure is associated with worsening 
of glucose intolerance during pregnancy and it also affects neonatal outcome in an 
adverse way. 
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21±3.7) residing in an arsenic affected area of Bangladesh, were subjected to a 2 sample 
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level of As in the usable (drinking, cooking, washing and bathing) water at the 
respective households and total urinary arsenic level. GDM was diagnosed by WHO 
criteria and neonatal outcome was assessed using APGAR Score measured by a 
Specialist Obstetrician. Serum glucose was measured by Glucose Oxidase method and 
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significant positive correlation with WAs levels (r=0.429;p=<0.001) and water arsenic 
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0.233; p=0.041) with WAs level. Chronic arsenic exposure is associated with worsening 
of glucose intolerance during pregnancy and it also affects neonatal outcome in an 
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1. INTRODUCTION 
 
1.1 Background:  
Arsenic exposure is a well-recognized public health problem. Millions of people world-
wide are potentially exposed predominantly to inorganic arsenic from drinking water 
contaminated by naturally occurring sources (Tchounwou et al, 1999). Chronic 
exposure to arsenic is associated with a number of adverse health effects (Yoshida et al, 
2004). Accumulating evidence has shown an increased risk of type 2 diabetes in general 
populations exposed to arsenic, but little is known about exposures during pregnancy 
and the association with gestational diabetes (Ettinger et al, 2009). 
 
Chronic exposure to arsenic through drinking water has the potential to cause adverse 
pregnancy outcomes, the association between arsenic in drinking water and spontaneous 
abortion, stillbirth, low Apgar score and neonatal death has been noticed (Milton et al, 
2005). 
 
1.2 Prevalence of arsenic contamination 
Arsenic (As) contamination of ground water has been reported from different parts of 
the world and is gradually evolving in to a global problem (Rahman et al, 2001; Tseng 
et al, 2005; Foy et al, 1992; Cebrian et al, 1983; Borzsonyi M et al, 1992;  Hopenhayn-
Rich et al, 1998). More than one hundred million people worldwide are at risk of 
elevated arsenic exposure. The situation is particularly problematic in Southeast Asia, 
where a large fraction of the many hand-pumped wells yield drinking water with arsenic 
concentrations above 10µg/L (Br Geol Survey, 2001), the drinking water guideline 
value of the World Health Organization (WHO, 2004). Millions of people 
worldwide rely on drinking water sources containing arsenic; in the U S, about 13 
million people live where arsenic levels in public drinking water supplies exceed the 
U.S. Environmental Protection Agency's standard (Navas-Acien et al, 2008). 
Bangladesh and West Bengal, a province of India, are the two most affected regions in 
the world (Smith  et al, 2000; Mandal et al, 1996) 
 2 | P a g e  
 
 
Until recently groundwater has been the principal source of drinking water for more 
than 80% of the Bangladeshi population [United Nations Children’s Fund (UNICEF), 
1998]. It is estimated that 35 to 77 million people in Bangladesh are exposed to As 
mainly through the drinking of contaminated water (Argos M et al, 2010). Since 1993, 
World Health Organization has recommended the provisional guideline value for As 
concentration in drinking water to be 10 µg/L. (WHO, 2011). 
 
The arsenic contamination problem in Bangladesh is rapidly emerging. In December, 
1995 it was estimated that only 10 million people were at risk of arsenic exposure 
through tube-well water. Until 1995, the arsenic contamination situation in West 
Bengal, India, was believed to be the greatest arsenic disaster in the world (Ahmad et al, 
1999). However, in the following years, arsenic contamination in groundwater in 
Bangladesh became apparent, and the situation is now considered as the largest in the 
world (Ahmad et al, 2000). 
 
Chronic exposure to arsenic may affect all of the organs and systems of the human 
body. Arsenic readily crosses the placental barrier and thus affects fetal development. 
Reproductive and developmental effects of inorganic arsenic on humans and on animal 
species have been reported (Hood et al, 1988; Gerver  et al, 1988; Concha et al, 1982; 
Zierler et al, 1998). In contrast, there are few reports about effects of arsenic in drinking 
water on human pregnancy outcomes (Borzsonyi et al, 1992, Aschengrau et al, 1989). 
Higher spontaneous abortions (69.57/1,000 live births) and stillbirths (7.68/1,000 live 
births) were observed in the high arsenic area (where drinking water arsenic > 0.1 
mg/L), compared to the control area (where drinking water arsenic < 0.1 mg/L); among 
controls, the rates for spontaneous abortions and stillbirths were 51.14/1000 live births 
and 2.84/1,000 live births, respectively (Borzsonyi  et al, 1992). Gestational diabetes 
has an estimated prevalence of 1–14% of all pregnancies depending on race or ethnicity 
and diagnostic criteria used [American Diabetes Association (ADA) 2004; Ferrara et al, 
2007]. 
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1.3 Arsenic exposure and health effect 
Exposure during pregnancy was associated with increased risks of morbidity (e.g. 
diarrhea) among pregnant women; (Ahmad SA et al, 2001) pregnancy complications 
(Raqib et al, 2009; Von Ehrenstein et al, 2006; Milton et al, 2005) as well as infant 
mortality (Raqib et al, 2009; Rahman et al, 2007) and morbidity (e.g. respiratory 
infection) (Ahmad et al. 2001, Rahman et al. 2011). The uncovering of increasing 
number of adverse effects due to maternal As exposure shows that it is an emerging 
public health problem in Bangladesh (Ser et al, 2015). 
 
Health effects associated with long-term consumption of arsenic-contaminated water 
include cancers of the bladder, kidney, lung, and skin (Borzsonyi, Bereczky  and 
Rudnai ,1992; Hopenhayn-Rich , Biggs and Smith ,1998; Br. Geol. Surv. 2001; World 
Health Organization 2004), as well as chronic non-malignant conditions, the most 
frequently observed being characteristic skin lesions (Haque , Mazumder and 
Samanta,2003;National Academy Press, 2001). Although recently more attention has 
been focused on the reproductive health effects of arsenic, the findings are still 
inconclusive (Ahmad , Sayed and Barua ,2001; Hopenhayn-Rich, Browning and Hertz-
Picciotto ,2000; Borzsonyi, Bereczky and Rudnai ,1992; Yang , Chang and Tsai 
,2003;Aschengrau , Zierler  and Cohen ,1989; Ihrig , Shalat  and Baynes ,1998). 
 
Arsenic-induced diabetes may occur through induction of insulin resistance and beta-
cell dysfunction by arsenic (or its methylated metabolites) via induction of oxidative 
stress or interferences in signal transduction or gene expression (Tseng 2004). 
Individual factors (e.g., nutritional status, genes) may also influence arsenic toxicity 
(Vahter et al, 2007).  
 
Inorganic arsenic is an established potent human carcinogen, causing cancer in skin, 
lungs, urinary bladder, and kidney, and possibly also in liver, prostate, and ovaries (Intl. 
Agency Res. Cancer. 2004;Waalkes, Liu and Diwan 2007). Even drinking water 
concentrations around 10 µg/L, which is the standard in many countries, are associated 
with an appreciable cancer risk, on the order of 0.1%–0.3% (Natl. Res. Counc. 2001). In 
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addition, chronic arsenic exposure is associated with increased risk of numerous non 
cancer effects, e.g. hyperkeratosis; pigmentation changes; cardiovascular diseases 
including hypertension; respiratory effects; neurological, liver, and kidney disorders; 
and diabetes mellitus (Intl. Agency Res. Cancer. 2004; Natl. Res. Counc. 2001;World 
Health Org./Intl. Prog. Chem. Safety. 2001). 
 
All these modes of action are highly relevant for maternal and fetal health. Still, the 
arsenic-related health effects have mostly been documented in adult populations in 
general, and little is known about variation insusceptibility depending on gender and 
age (Vahter et al, 2007). Usually, the developing organism is particularly vulnerable to 
toxic insult, because of rapid cell division and differentiation, especially in the brain 
(Grandjean and Landrigan, 2006). Because arsenic easily passes the placenta (Concha et 
al ,1998), exposure during pregnancy may be critical. In the following, the state of the 
art concerning the consequences of arsenic exposure for maternal health and early-life 
development is discussed. 
 
1.4 Arsenic Exposure and Maternal Health 
Despite the high prevalence of elevated arsenic exposure worldwide and the 
documented toxicity of arsenic, very few studies have investigated the effects on 
maternal health.  
 
1.4.1 Hypertension: In a large cross-sectional study in Inner Mongolia, even fairly low 
water arsenic concentrations (20–50 µg/L) were associated with increased systolic 
blood pressure in women six weeks post partum (Kwok et al,2007). It was suggested 
that the cardio vascular challenge in pregnancy increased the susceptibility to arsenic.  
 
1.4.2 Anemia: There is also certain evidence that arsenic may cause anemia, probably 
by destabilizing membranes (Biswas 2008) and decreasing the delta-aminolevulinic 
acid dehydratase activity (Kannan et al,2001), especially during pregnancy. Exposure to 
moderately elevated arsenic concentrations in drinking water (40 µg/L)in Antofagasta, 
northern Chile, was found to be associated with a higher rate of anemia during 
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pregnancy compared to that in Valparaiso, at own with essentially no arsenic in the 
drinking water (Hopenhayn et al,2006 ). Prevalence of anemia increased more sharply 
among the exposed women. This may be a serious effect of arsenic as iron deficiency in 
women is a common phenomenon in late pregnancy and may result in complications for 
both mother and child (Kumar et al ,2008; Mahajan et al ,2008). Interestingly, a recent 
study from Bangladesh showed a negative association between individual measures of 
arsenic exposure (urine concentrations) and hemoglobin concentrations in men but not 
in women (Heck et al ,2008). Only in the small fraction of women with hemoglobin 
concentrations below 100 g/L was elevated arsenic exposure (more than 100 µg/L in 
urine) associated with decreased hemoglobin concentrations. 
 
1.4.3 Hormonal disturbance: Given that arsenic interacts with steroid hormones and 
estrogen in particular, it seems likely that arsenic exposure may have additional adverse 
effects on maternal health and child development as well as on women’s health more 
generally. Indeed, recent studies indicate increased age at menarche in Indian girls 
exposed to arsenic through drinking water (Sen and Chaudhuri, 2007; Sengupta 2004). 
Exposure of female rats to arsenite in drinking water over seven estrous cycles caused a 
significant reduction in plasma levels of leutinizing hormone (LH), follicle-stimulating 
hormone (FSH), and estradiol, along with a significant follicular and uterine cell 
degeneration and decreases in ovarian steroid-metabolizing enzymes and ovarian and 
uterine glutathione peroxidase (Chattopadhyay 2003). Selenium supplementation 
restored the plasma hormone levels and prevented the arsenic-induced histopathological 
changes in ovaries and uterus.  
 
1.4.4 Tumors: In utero exposure of mice to fairly high arsenic concentrations (42 or 85 
mg/L in drinking water during gestational days 8–18) showed a marked increase in 
ovarian and lung tumors as well as uterine and oviduct hyperplasia in the females at 
adult age (Waalkes , Liu and Diwan  2007). This indicates that arsenic-related effects on 
women’s health may be induced prenatally. 
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1.4.5 Skin diseases: One population-based study on arsenic-induced health effects in 
Bangladesh, which is one of the few designed to evaluate gender differences in arsenic-
related health effects (Rahman 2006), showed that the lower risk of arsenic related skin 
lesions in women largely is explained by the more efficient metabolism of arsenic in 
women compared to men (Lindberg  2008). On the other hand, epidemiological studies 
that have reported data for men and women separately, although not directly 
comparable, indicate that women may be more sensitive to certain arsenic-related toxic 
effects (Vahter  2007). Obviously, more studies designed to evaluate these issues are 
needed. 
 
1.4.6 Oxidative stress: Arsenic could influence diabetes development by mechanisms 
involving oxidative stress, inflammation, or programmed cell death (apoptosis) (Navas-
Acien et al, 2006). Rat pancreatic beta cells treated with arsenic showed impaired 
insulin secretion and function (Diaz-Villasenor et al, 2006). This impaired insulin 
secretion (even by low level arsenic exposure) may disturb beta cell function via a 
mechanism involving oxidative stress (Fu et al. 2010). Other experimental studies 
showed that arsenic can affect beta cells, increasing beta cell apoptosis (programmed 
cell death) by causing oxidative stress. Arsenic can decrease insulin secretion as well as 
beta cell viability (Lu et al, 2011). 
  
Arsenic exposure during pregnancy has been found to affect the immune cells in the 
placenta and umbilical cord blood, via inflammation and oxidative stress. Prenatal 
exposure to arsenic, then may affect the function of the immune system of the baby, and 
have consequences for diseases later in life (Ahmed et al, 2010). Arsenic is an 
endocrine (hormone) disruptor. In animals and cell cultures, arsenic can disrupt 
hormonal (endocrine) processes, including glucocorticoid, estrogen, androgen, 
progesterone, and thyroid receptors, as well as gene expression, at low doses similar to 
those found in the environment (Davey et al, 2008).    
 
1.4.7 Gestational diabetes: There is also evidence that arsenic exposure may increase 
the risk of gestational diabetes. A study has found that pregnant women who had higher 
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arsenic levels also had higher blood glucose levels after a glucose tolerance test. This 
finding implies that arsenic may impair glucose tolerance, and may be associated with 
an increased risk of gestational diabetes. The women in this study lived near a 
hazardous waste site, and had arsenic levels higher than those in unexposed people, but 
their exposures were still "relatively low" (Ettinger et al, 2009). 
 
1.5 Mechanisms  Consideration 
Pregnancy implies considerable stress on maternal metabolism. This is particularly true 
for one-carbon metabolism because methyl groups, as well as folate and choline, are 
critical for placental and fetal development. Elevated levels of Hcy in maternal plasma 
have been associated with pre-eclampsia, placental abruption, adverse pregnancy 
outcomes, and infertility (Braekke et al,2007;Forges et al, 2007; Refsum et al,2006)). 
To support the remethylation of produced Hcy and to meet the fetal demand of choline 
for brain development, PEMT is up-regulated in pregnancy to increase the de novo 
synthesis of choline in maternal liver (Zeisel  2006). Betaine, the oxidation product of 
choline and the form delivering the methyl group to Hcy, becomes increasingly 
important during pregnancy for adjusting the Hcy level (Velzing-Aarts 2006), 
especially in women with low serum concentrations of folate and methionine (Wallace 
2008). Obviously, this betaine-dependent remethylation of Hcy by BHMT is 
particularly important for arsenic-exposed women. In fact, the methylation of inorganic 
arsenic to DMA increases during the course of pregnancy (Concha et 
al,2003;Hopenhayn et al,1998; Vahter  2007). 
 
1.6 Impaired Fetal Growth 
There are certain indications of impaired fetal growth in mothers exposed to arsenic via 
drinking water during pregnancy (Hopenhayn et al,2003;Yang et al,2003).Two 
ecological cross-sectional studies from north eastern Taiwan (up to 3600 µg/L; 85% 
above 50 µg/L in the drinking water) and northern Chile (on average 40 µg/L in the 
water) showed non significant decreases in birth weight of 30 and 57 grams, 
respectively (from 3133 and 3398g, respectively). Our recent population-based cohort 
study involved 1578 mother-infant pairs in rural Bangladesh, with measurements of 
 8 | P a g e  
 
arsenic concentrations in maternal urine samples collected in early and late gestation 
(median 80 µg/L, 90th percentile 400 µg/L). Arsenic exposure showed a significant 
negative association with size at birth at urine arsenic concentrations below 100 µg/L, 
but no further effect at higher exposure levels. The reason for this dose-response pattern 
is not known. The total As-associated decrease in birth weight was 170 g (average birth 
weight 2681 g), and the head and chest circumferences were reduced by 5 mm and 14 
mm, respectively. 
 
1.7 Mechanisms of Fetal Toxicity 
Considering the high placental transfer of arsenic and its documented toxicity, the 
reported effects on fetal development seem to be less strong than could be expected, 
especially in populations with prevalent poor nutrition. Possibly, the increased 
methylation efficiency during pregnancy results in less arsenic being transferred to the 
fetus (Hood et al,1988), either because of the increased rate of excretion in maternal 
urine with advancing gestation (Concha et al,1998) or variation in the rate of transfer 
among the arsenic metabolites, as discussed above. Also, the methylated arsenic 
metabolites, at least in their pentavalent form, are less fetotoxic (Hood  1998; Irvine , 
Boyer and  DeSesso 2006). As there is a wide inter individual variation in arsenic 
methylation, it is important to evaluate whether women with low methylation capacity, 
either due to genetic polymorphisms or otherwise impaired one carbon metabolism, are 
more susceptible to arsenic-induced adverse pregnancy outcomes. 
 
1.8 Arsenic contamination 
Arsenic is a ubiquitous metalloid element in the bedrock, sediments, and soils. From 
these minerals and deposits, it is easily dissolved to surrounding aquifers. Therefore, 
drinking water derived from groundwater is a common source of human exposure to 
inorganic arsenic (Intl. Agency Res. Cancer. 2004;Natl. Res. Counc. 2001). In addition, 
people may be exposed via ambient air in areas with industrial emissions or coal 
burning, particularly when arsenic-rich coal is used for indoor stoves in poorly vented 
homes (Wang et al,2009). 
 
 9 | P a g e  
 
An increasingly important source of exposure to inorganic arsenic is food, such as 
cereals and vegetables, especially in areas where arsenic-rich groundwater is used for 
irrigation (e.g.Adomako et al,2009). Highly elevated arsenic concentrations in seafood 
consist mainly of arsenobetaine, arsenocholine, and arsenosugars, which are of less 
toxicological significance but need to be considered when arsenic in urine is used as an 
indicator of exposure to inorganic arsenic. 
 
 
 
 
Figure 1.1: preterm stimulation of fetal- placental endocrine system by uterine stretch 
(Vahter, 2009) 
 
Arsenic is a highly potent toxicant and carcinogen (International Agency for Research 
on Cancer 2004; National Research Council (NRC) 2001). Worldwide, millions of indi-
viduals are drinking well water with arsenic levels above the World Health 
Organization (WHO) guideline value of 10 µg/L (Kinniburg, 2001; Nordstrom, 2002; 
WHO, 2004). Arsenic concentrations are high in certain geologic formations, and 
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arsenic can dissolve easily to groundwater and contaminate local tube wells and other 
public water supplies. This has been a problem in many parts of the world, including 
Argentina, Bangladesh, Chile, China, Hungary, India, Taiwan, and parts of the United 
States (Chowdhury et al, 2000; Nordstrom, 2002; Smith, 2000). 
 
Millions of people worldwide are potentially exposed predominantly to inorganic 
arsenic from drinking water contaminated by naturally occurring sources(Tchounwou et 
al, 1999). 
 
1.9 Arsenic toxicity with glucose intolerance: 
Arsenic-induced diabetes may occur through induction of insulin resistance and beta-
cell dysfunction by arsenic (or its methylated metabolites) via induction of oxidative 
stress or interferences in signal transduction or gene expression (Tseng, 2004). 
Individual factors (e.g., nutritional status, genes) may also influence arsenic toxicity 
(Vahter, 2007).  
 
Few studies have explored the effects of arsenic on human pregnancy outcomes (Huyck 
et al, 2007; Rahman et al, 2007; Vahter et al, 2006) and none have investigated risk of 
diabetes in pregnant women, even though diabetes is a major potential complication of 
pregnancy with adverse effects for both mothers and infants.  
 
Gestational diabetes (GD) occurs when resistance to circulating insulin leads to 
hyperglycemia, and this impaired glucose metabolism is first detected during 
pregnancy. GD has an estimated prevalence of 1–14% of all pregnancies depending on 
race/ethnicity and diagnostic criteria used (ADA, 2004; Ferrara, 2007). 
 
GD is associated with 30–60% increased risk of developing diabetes in later life in the 
mother and also poses intergenerational risks to the fetus (Metzger, 2007). Diabetes in 
pregnancy is associated with increased risk of major congenital malformations, 
macrosomia (birth weight > 4,000 g or > 90th percentile for gestational age), and 
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complications during delivery and in the perinatal period including stillbirth (Fetita et 
al, 2006). 
 
1.10 Arsenic toxicity with birth defects 
Arsenic crosses the placenta in both animals(Hanlon and Ferm,1987) and 
humans,(Concha  et al,1998) and experimental studies support a role for arsenicas a 
developmental toxicant. Reproductive studies in anarsenic-contaminated community 
surrounding a Swedish copper smelter found that women working in the smelter or 
living nearby gave birth to infants of lower birth weight, and had a higher incidence of 
spontaneous abortions and congenital malformations (Nordstrom ,Beckman and  
Nordenson,1978; Nordstrom ,Beckman and  Nordenson,1979). Although arsenic levels 
were high, confounding from other chemicals or lifestyle factors could not be excluded. 
Studies around a copper smelter in Bulgaria found a higher incidence of toxemia in 
pregnant women (Tabacova et al,1994)and lower birth weight in newborns,(Tabacova 
et al,1994) but again, the results were limited by methodologic concerns. 
 
Investigations focused on arsenic exposure from drinking water have reported increased 
rates of miscarriage (Aschengrau, Zierler and Cohen,1989;Borzsonyi et 
al,1992)stillbirths (Borzsonyi et al,1992)and congenital heart disease(Engel and 
Smith,1994;Zierleret al,1988).In the county of Antofagasta, Chile, rates of stillbirths 
and infant mortality increased over a time period coinciding with a substantial increase 
in the arsenic concentration (from 90 ug/L to 800ug/L) in the local public drinking 
water supply (Hopenhayn-Rich et al, 2001).A retrospective survey of mothers in 
Bangladesh compared self reported  pregnancy outcomes in two villages with 
contrasting arsenic levels in drinking water (mean 240 ug/L vs. 20ug/L), and found 
increases in miscarriages, stillbirths and preterm births in the more highly exposed 
village(Ahmad et al, 2001). 
 
Exposure to elevated levels of inorganic arsenic (iAs) in drinking water is a major 
public health concern because iAs has been linked with numerous adverse health 
outcomes (Kapaj et al, 2006; Rahman et al, 2009). The detrimental effects from long-
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term exposure include skin lesions, cardiovascular disease, peripheral vascular disease, 
diabetes mellitus, and cancers of the urinary bladder, skin, lung, liver, and prostate (Del 
Razo et al, 2011; International Agency for Research on Cancer, 2004; Maull et al, 
2012; Rahman et al, 2009; Tseng, 2007). It is also evident that certain populations, 
including pregnant women and their unborn children, are particularly susceptible to the 
adverse effects of iAs exposure(Vahter, 2009). For instance, prenatal iAs exposure has 
been associated with a greater risk of adverse pregnancy outcomes such as preterm 
birth, low birth weight, and or fetal loss (Vahter, 2009). 
 
1.11 Apgar score: 
Virginia Apgar (1909-1974) was an American obstetrical anesthesiologist. She was a 
leader in the fields of anesthesiology and teratology,and introduced obstetrical 
considerations to the established field of neonatology. To the public, however, she is 
best known as the inventor of the Apgar score, a way to quickly assess the health of 
newborn children immediately after birth. 
 
Apgar score is used for rapid assessment of newborns.Low five-minute Apgar score has 
been associated with increased risk of severe neurologic outcome, but data on milder 
outcomes, particularly in the long term, are limited. We aimed to examine the 
association of five minute.Apgar score with prevalence of neurologic disability and with 
cognitive function in early adulthood. 
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Figure 1.2: Apgar scoring system ( source: Google) 
 
The test is generally done at one and five minutes after birth,and may be repeated later 
if the score is and remains low. Scores 7 and above are generally normal, 4 to 6 fairly 
low, and 3 and below are generally regarded as critically low. 
 
A low score on the one-minute test may show that the neonate requires medical 
attention (Casey,McIntire and Leveno,2001), but does not necessarily indicate a long-
term problem, particularly if the score improves at the five-minute test. An Apgar score 
that remains below 3 at later times such as 10, 15, or 30 minutes may indicate longer-
term neurological damage, including a small but significant increase in the risk of 
cerebral palsy. However, the Apgar test's purpose is to determine quickly whether a 
newborn needs immediate medical care. It is not designed to predict long term health 
issues (Curr. Res. Anesth. Analg, 1953) 
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A score of 10 is uncommon, due to the prevalence of transient cyanosis, and does not 
substantially differ from a score of 9. Transient cyanosis is common, particularly in 
babies born at high altitude. A study that compared babies born in Peru near sea level 
with babies born at very high altitude (4340 m) found a significant average difference in 
the first Apgar score, but not the second. (Gonzales and Salirrosas ,2005) 
 
In recent years, doubts have been cast on the value of the Apgar score. Studies found 
that the Apgar score failed to predict specific neurologic outcomes of the term infants, a 
use for which it was never intended(Nelson and Ellenberg ,1981). What’s more, it was 
once inappropriately adopted alone to diagnose asphyxia (AAP Committee on Fetus and 
Newborn and ACOG Committee on Obstetric Practice ,2006). 
 In order to place the Apgar score in its proper perspective, the Neonatal Resuscitation 
Program Guidelines state that ‘‘Apgar scores should not be used to dictate appropriate 
resuscitation actions, nor should interventions for depressed infants be delayed until the 
1 minute assessment’’ (Vahter 2009).Furthermore, the Apgar score also has its own 
limitations. A number of factors may influence an Apgar score such as drugs, trauma, 
congenital anomalies, infections, hypoxia, hypovolemia,and preterm birth. Up to date, 
there are few consistent data on the significance of the Apgar score in preterm infants. 
Because elements of the score such as tone, color and reflex irritability partially depend 
on the physiologic maturity of the infants, this situation may lead to a healthy preterm 
infant with no evidence of asphyxia receiving a lower score only because of immaturity 
(AAP Committee on Fetus and Newborn and ACOG Committee on Obstetric Practice 
,2006). 
 
Association of Apgar score at five minutes with long-term neurologic disability and 
cognitive function.Most newborns with Apgar scores below 7 grow up healthy, but risks 
of neuro developmental disability among them are greater than among those with higher 
Apgar scores, particularly in the short term(Thorngren-Jerneck and Herbst,2001;Nelson 
and Ellenberg,1984; Moster et al,2001; Sun et al,2006). 
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Increased risks have been reported for neonatal seizures (Cebrian et al,1983); neonatal 
intracranial hemorrhage (Thorngren-Jerneck and Herbst,2001); cerebral palsy 
(Thorngren-Jerneck and Herbst,2001;Nelson and Ellenberg,1984;Moster et al,2001); 
mental retardation (Thorngren-Jerneck and Herbst,2001); and epilepsy (Sun et al,2006; 
Ehrenstein et al, 2006). There are also reports of association between five-minute Apgar 
scores below 7 and risk of motor and developmental impairments at school age, 
including symptoms of attention deficit (Moster , Lie and Markestad, 2002) and speech 
and language problems (Krebs , Langhoff-Roos and Thorngren-Jerneck, 2001). Less is 
known about long-term or mild neurodevelopment disability among newborns with low 
Apgar scores.  
 
Moreover, no published study is available on pregnancy outcomes in relation to arsenic 
exposure through drinking water in Bangladesh. Therefore, we explore this study was to 
identify pertinent information regarding pregnancy outcomes of the women who were 
chronically exposed to arsenic through drinking water, and also to estimate the Apgar 
score and association between adverse pregnancy outcomes in exposed and non-
exposed groups. 
 
1.12 Objectives 
 
1.12.1 General Objectives: The general objective was undertaken to explore the 
association of chronic arsenic exposure with gestational diabetes mellitus (GDM) and 
neonatal outcome in a Bangladeshi population. 
 
1.12.2 Specific Objectives:  
The specific objectives of the study were: 
• To investigate the arsenic exposure during pregnancy in arsenic affected area. 
• To assessed the maternal and neonatal outcome in arsenic exposure mother. 
• To explore the association between arsenic affected mother with maternal and 
neonatal outcome. 
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2. METHODOLOGY 
 
2.1 Study design: 
It was an observational cross-sectional study. The study comprised face to face 
interview and urine, blood and using water sample were analyzed. 
 
2.2 Study area:  
This study was conducted in three rural districts of the People’s Republic of 
Bangladesh, Chandpur, Faridpur and Madaripur. These districts were selected based on 
evidence of presence of arsenic (As) -contaminated tube wells. Databases from the local 
public health offices recorded 73%, 26% and 79% of tube wells with As levels higher 
than 50 g/L in the Sadar (district center) of Chandpur, Faridpur and Madaripur 
respectively. These records were provided to the government offices through nation-
wide surveys conducted by local health workers and non-governmental organizations in 
2003. 
 
2.3 Study period:  
Total study period started from 4th January to 6th December, 2014. The study period 
expanded with literature review and protocol preparation,data analysis and final thesis 
submission. Data were collected March to August 2014 Study period.  
 
2.4 Study participants:  
We recruited 317 pregnant women and used datasets from 263 (age in yrs, M±SD, 
21±3.7) pregnant women residing in an arsenic affected area of Bangladesh and 54 
mothers exclude the final analysis.  
 
The participants for this study were pregnant women and their newborns with no known 
medical conditions. The recruitment of participants started from March to August 2014. 
It was carried out at one hospital and clinic at each district. Most of our participants 
were in their later half of the second or third trimester when enrolled. Pregnant women 
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who were in the early second trimester were invited to return for recruitment when they 
reached the later stage of pregnancy.  
 
Gynecologists of each centre conducted health checks for pregnancy complications such 
as preeclampsia, intrauterine growth restriction, placenta previa, and placental 
abruption; medical history such as diabetes mellitus and renal disease; and neonatal 
outcome was assessed using Apgar score measured by a Specialist 
Obstetrician.Pregnant women who had tobacco and alcohol consumption habits and 
non-singleton birth history were excluded in this study.  
 
2.5 Inclusion criteria 
• Screening of women with at 27-38 weeks of gestation.    
• Previous history of GDM or glucose intolerance. 
• History of GDM-associated adverse pregnancy outcomes and  
• Maternal age ≥25 yrs. 
• No pre-existing diabetes mellitus. 
 
2.6 Exclusion criteria 
• Multi fetal pregnancy.  
• History of non-singleton birth. 
• Any disease that affected pregnancy e.g. thyroid disorder, heart disease, 
hypertension etc. 
• Mental illness 
 
2.7 Data collection procedure: 
Local health workers were recruited to administer informed consent was taken from 
each subject (fulfilling the inclusion criteria) in an appropriate form (Appendix-I). The 
exact nature and purpose of the study was explained to gestational diabetes in short and 
were asked for the willingness to participate and then motivated them to visit clinical 
laboratory for the blood investigation.The study participants to collect the following 
information: age, education, occupation, time living at residence, smoking status and 
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alcoholic beverage consumption during pregnancy (both defined as yes or no and 
frequency), daily prenatal supplement intake (yes or no), residence location (urban or 
rural), source and daily consumption of drinking and cooking water, and source of 
bathing water. In addition, information on previous pregnancy outcomes including 
number of pregnancies and number of previous pregnancy losses was gathered from 
questionnaires. Information on birth outcomes/measures including newborn birth 
weight, newborn length, gestational age, head circumference, placental weight, and 5-
min Appearance, Pulse, Grimace, Activity, Respiration (APGAR) score was gathered at 
time of delivery by the physician. 
 
Social demographic data including: age, education, occupation, and socioeconomic 
status (SES) were recorded. To analyze SES, information on possession of assets (table, 
chair or bench, wrist watch or clock, bed, radio, colored TV, refrigerator, bicycle and 
mobile phone), and household status (availability of electricity, number of rooms, 
presence of flushed toilets, and building materials for roof, walls and floorings) was 
collected. Participants were also asked their last menstrual periods and parity. 
Gestational week at the time of maternal sampling was calculated from the dates of 
sample collection and last menstrual period.  
 
At delivery, recruited local nurses recorded the birth date and mode of delivery. The 
length of gestation was calculated from the dates of delivery and last menstrual period. 
Information collected for the newborn included sex, Apgar score, recumbent length and 
birthweight. 
 
Data on adverse outcomes were collected, including preterm birth (gestational age < 37 
weeks), low birth weight (LBW; < 2,500 g), small for gestational age (SGA; birth 
weight < 10th percentile), and large for gestational age (LGA; birth weight > 90th 
percentile). SGA and LGA categories were based on newborn data collected from 
northern regions of Mexico (Montes-Nunez et al, 2011; Rios et al, 2008). During 
hospitalization, a protocol clinical examinationof the newborns was performed.  
Anthropometric data were measured once, before breast feeding started. 
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Infants were weighed without diapers and using anelectronic digital infant scale. Length 
was measured in the supine position, using a stadiometer composed of a stationary 
head-board and a movable footboard. Knees and hipswere extended using gentle force 
and the footboard pressedagainst the balls of the feet (BMC Public Health 2013).  
 
The Apgar score was measuredon a scale from 1 to 10, at 1 and 5 minutes after 
delivery.Infants were evaluated on a scale of 0 to 2 according to five categories (skin 
color, muscle tone, reflexes, respiratory effortand heart rate), and the points from each 
category added together to determine the total score. 
 
2.8 The Apgar score was measured by following signs used are as follows: 
  
2.8.1 Heart Rate: This was found to be the most important diagnostic and prognostic of 
the five signs. A heart rate of 100-140 was considered good and given a score of two, a 
rate of under 100 received a score of one, and if no heart beat could be seen, felt or 
heard the score was zero.  
 
2.8.2 Respiratory Effort: An infant who was apneic at 60 seconds afterbirth received a 
score of zero, while one who breathed and cried lustilyreceived a two rating. All other 
types of respiratory effort, such as irregular, shallow ventilation were scored one. An 
Apgar scale (evaluate @ 1 and 2 minutes postpartum) 
 Sign 2 1 0 
A Activity (muscle 
tone) 
Active Arms and legs 
flexed 
absent 
P Pulse >100 bpm <100 bpm absent 
G Grimace (reflex 
irritability) 
Sneezes, coughs, 
pulls away 
grimaces No response 
A Appearance(skin 
color) 
Normal over 
entire body 
Normal except 
extremities 
Cyanotic or 
pale all over 
R Respirations Good, crying Slow, irregular absent 
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infant who had gasped once at thirty or forty-five seconds after birth, and who then 
became apneic, received a zero score, since he was apneic at the time decided upon for 
evaluation. 
  
2.8.3 Reflex Irritability: This term refers to response to some form of stimulation. The 
usual testing method was suctioning the oropharynx and nares with a soft rubber 
catheter which called forth a response of facial grimaces, sneezing or coughing. 
Although spontaneous micturition and defecation are not a response to an applied 
stimulus, they were considered to be favorable signs if they occurred. 
  
2.8.4 Muscle Tone: This was an easy sign to judge, for a completely flaccid infant 
received a zero score, and one with good tone, and spontaneously  flexed arms and legs 
which resisted extension were rated two points. We are unable to agree with Flagg's 
description of spasticity (Flagg ,1944) as a sign of asphyxiation of the infant. The use of 
analeptics in the baby did not influence this score because of the standardized early time 
of observation and rating. 
  
2.8.5 Color: This is by far the most unsatisfactory sign and caused themost discussion 
among the observers. All infants are obviously cyanotic at birth because of their high 
capacity for carrying oxygen and theirrelatively low oxygen content and saturation 
(Eastman,1930).The disappearance ofcyanosis depends directly on two signs previously 
considered respiratory effort and heart rate.  
 
Comparatively few infants were given a full score of two for this sign, and many 
received zero in spite of their excellent   score for other signs. The foreign material so 
often covering the skin of the infant at birth interfered with interpreting this sign, as did 
the inherited pigmentation of the skin of colored children, and an occasional congenital 
defect. Many children for reasons still mysterious to us, persist in having cyanotic hands 
and feet for several minutes in spite of excellent ventilation, and added oxygen. A score 
of two was given only when the entire child was pink. Several hundred children were 
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rated at three or five minutes as well as at sixty seconds and in almost all cases a score 
of two could be given for color at these later times.  
 
2.9 Data collection technique 
Face to face interview in between fasting and 2 hr (OGTT) blood collection, 
participants were asked with questionnaires by the data collector. Each participant took 
approximately 20 minutes to complete the questionnaire. 
 
2.10 Anthropometric Measurement 
 
Weight 
Body weight was measured on a lever balance (Detecto-Medic, Detecto Scales, Inc, 
USA). The balance was calibrated every day before use. The body weight was 
measured bare footed to the nearest 0.1 kg with clothes on. The average weight (0.5 kg) 
of the clothes was later substracted from the measured weight. The measurement of 
weight done after the bladder has been emptied and before a meal. 
 
Height 
Heights of the subjects were measured barefooted in the standing position with a 
stander scale to the nearest 0.1 cm (Detecto-Medic, Detecto Scale Inc., USA). 
During measuring height some precautions were taken. When measuring height, the 
subjects stands straight with the head positioned such that the Frankfurt plane is 
horizontal, feet together, knees straight, and heels, buttocks and shoulder blades in 
contact with the vertical surface of the stadiometer. 
 
Method of calculation of Body Mass Index (BMI) 
Body mass index was calculated from the body weight and height of the subjects using 
the following formula weight in kg divided by height in meter Square.                
                 Weight in kg 
BMI  = ----------------------------- 
              (Height in meter) 2 
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2.11 Measurement of blood pressure as per ACOG (Fernando, 1993): 
 
Blood pressure measured in lying position keeping the sphygmomanometer at the level 
of heart. When systolic B.P more than 140 mm of Hg or diastolic BP more than 90 mm 
Hg it confirmed on two different occasions at least 6 hours apart. Hypertension is 
defined following the criteria of American College of obstetrics and Gynaecology 
(ACOG-Fernando, 1992) According to ACOG hypertension is defined as BP equal to as 
or more than 140/ 90 mm Hg; rise of systolic BP 30 mm Hg or rise of diastolic BP 15 
mm Hg or more.  
2.11.1 Pregnancy Induced Hypertension (PIH): Gestational hypertension (GH) and 
Preeclampsia (PE) are together considered as Pregnancy induced hypertension 
or PIH. 
 
2.12 Procedure of the Collection sample (Blood and Urine): 
 
Urine and blood samples were collected by recruited local phlebotomists. 
All participants were requested to fast over night (8-10hour) and not to take any kind of 
medicine or not to smoke on the previous day. They were requested to attend the sample 
collection room of the hospital on the next morning. 5 cc of fasting blood and 2cc two 
hour after 75 gm glucose were collected following all aseptic precaution from the ante-
cubital vein using disposable plastic syringe. Collected blood samples were kept in 
capped and airtight glass test tubes. Prior to sample collection the containers and test 
tubes were deionized as follows:  
 The container and test tubes were washed with detergent. 
 Those then were rinsed with double distilled deionzed water several times and 
then dried in an oven at 600C.  
After collection of samples the test tubes were sealed with parafilm. Serum was 
separated by centrifugation (10 minutes at a rate of 3000 rpm) at 200 C immediately 
after the blood was taken. Urine sample also collected same time with selected urine 
container. 
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2.12.1 Gestational Diabetes Mellitus (GDM):  
GDM diagnosis by WHO criteria (1999): 2hr post load glucose>=200mg/dl 
(11.1mmol/l) during an OGTT. The test should be performed as described by WHO 
using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in 
water.  
2.12.2 Diagnostic criteria for impaired glucose homeostasis 
           FPG >=110 to <126mg/dl (6.1 to 7.0mmol/l) 
 2hr post load glucose 140 to <200mg/dl (7.75 to 11.1mmol/l) 
2.12.3 Normal  
FPG <110mg/dl (6.1mmol/l) 
2 hr post load glucose <140mg/dl (7.75mmol/l) 
Separated serum was allocated in different eppendrop and preserved immediately at -
270C for the subsequent analysis. Before analysis sample was allowed to thaw and 
then analyzed for fasting glucose, 2 hours after glucose, triglyceride, total cholesterol. 
 
2.13 Measurement Arsenic exposure:  
2.13.1 Arsenic exposure by usable water:Degree of chronic arsenic exposure was 
assessed by the level of As in the usable (drinking, cooking, washing and bathing) water 
at the respective households. 
 
2.13.2 As exposure by Urine sample: 
Urine samples were diluted with 1.5% nitric acid and 2% 1-butanol, and filtered 
through 0.45 µm pore membranes. Maternal urinary-As (U-As) concentrations were 
measured using an octopole collision/reaction cell inductively coupled-plasma mass 
spectrometry (Agilent 7500 ce - Agilent Technology, Hachioji, Japan). Certified 
Reference Material No.18 “Human Urine” (National Institute for Environmental 
Studies, Tsukuba, Japan) was used for quality control. The mean detection limit was 
0.97 µg/L. 
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2.14 Statistical analysis 
The data obtained by questionnaire were first checked for the completeness by the 
investigator. After checking the completeness, coding was done. Data entry, cleaning, 
editing and final analysis was done in SPSS 16. Chi square test, frequency distribution 
used to analyze the association between the variables. P value of <0.05 considered 
sufficient for rejecting the null hypothesis of no difference among groups.   
 
2.15 Ethical considerations 
All necessary ethical and administrative approvals were obtained from the appropriate 
authorities before the commencement of the study.  The protocol was approved by the 
ethical review committee of Bangladesh University of Health Sciences before the start 
of study. Because of this study involved blood and Urine sample collection it needed it 
an invasive procedure and may rise strong ethical issues. Detailed information regarding 
the study objectives, procedure and risk and benefits involved were provided during 
first contact with participants. They had opportunity to discuss if they required further 
information and clarification. Informed written consent was obtained before the 
interview. All literate individual participants read the consent paper by themselves and 
signed. For the illiterate participants, the data collector read, translated and explained 
the consent paper to them and if they agreed, their thumb impression or sign was taken. 
Pregnant women were assured that all the information would be kept confidential and 
would only be used for research purpose. Social and cultural values of the pregnant 
mothers were respected and considered as required. Allocated interviewers were female. 
Subjects found to have adverse effect due to glucose intake were handled by the health 
professionals immediately. Scientific objectivity was maintained and personal harm to 
the subjects and respondents was guarded. Respondents or subjects were informed 
about the nature of the research methods that were used and they were free to withdraw 
from the study at any time. 
 
2.16 Laboratory analysis: 
2.16.1 The glycemic status of the subjects was assessed by:  
o Fasting Blood Glucose (FBG)  
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o 2 hour after 75 gm glucose (OGTT) 
Glucose level of the study subjects was measured by using Glucose Oxidase 
method (Randox, UK) (AppendixIII). 
 
2.16.2 Lipidemic status was assessed by: 
o Serum total cholesterol by enzymatic endpoint method (cholesterol Oxidase/ 
Peroxidase) (Randox Laboratories, UK) (Appendix IV) 
o Serum triglyceride by enzymatic-colorimetric (GPO-PAP) method (Randox 
laboratories, UK) (Appendix V) 
o Estimation serum High Density Lipo protein by enzymatic colorimetric (cholesterol 
CHOD-PAP) methodin auto analyzer (Analyzer Medical System, Rome, Italy) 
(Friedewald WT, 1972) 
o LDL cholesterol level in serum was calculated by using by Friedewald formula 
(Friedewald WT. 1972) 
2.16.3 As level in water (WAs) was measured by ultraviolet/visible                       
spectrophotometry. (Appendix-VIII) 
2.16.4 Urinary-As was measured by inductively coupled plasma-mass spectrometry 
and adjusted with specific gravity (U-AsSG). (Agilent 7500cc-Agilent 
Technology, Hachioji, Japan). 
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Table 3.1: The socio-demographic status of all  pregnant women (n=263): 
Characteristic n(%) 
Education 
-Illiterate 13 (4.9%) 
-Completed primary school 78(29.68%) 
-Completed secondary or higher school 162(61.59%) 
-Completed college or above 10(3.83%) 
Occupation  
Housewife 253(96.2%) 
Service 10(3.8%) 
Region 
-Chandpur 53 (20.17%) 
-Faridpur 83 (31.55%) 
-Madaripur 127 (48.28%) 
Area   
-Urban 64(24.33) 
-Rural 145(55.14) 
-Semi urban 54(20.53) 
 Source of cooking water 
- Tube well 121 (41.8%) 
- Pond/river 110 (46.0%) 
- Tap (deep tube well or filtered pond 
water) 
32 (12.2%) 
Source of drinking water 
- Tube well 193 (73.38%) 
- Pond/river 2 (0.77%) 
- Tap (deep tube well or filtered pond 
water) 
68 (25.85%) 
Results are expressed as Mean± SD. n= number of subjects. Percentages were analyzed 
by cross tab analysis. 
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Table 3.2: The Maternal status of study Non-GDM and GDM subjects 
 
Results are expressed as number and (percentages, %) n= number of subjects. The 
significance difference was analyzed by cross tab chi squire test. Significance level 
were calculated p<0.05.  
 
3.5 Clinical characteristics of the study participants 
The clinical characteristics of Non-GDM and GDM subjects are shown in Table 3.3. 
The Age parameter (years,M±SD) showed no significant difference between GDM and 
Non-GDM subjects.  The Body mass index (kg/m2,M±SD) showed significantly higher 
in GDM subjects (25.5±3.7) compare to the Non-GDM subjects (23.31±3.1), 
(p<0.001).The Systolic blood pressure (mm of Hz, M±SD) ) showed significantly 
higher in GDM subjects (113.9±11.2) compared to the Non-GDM subjects 
(80±4.5),(p<0.023).The Diastolic blood pressure (mm of Hz, M±SD) showed 
significantly higher in GDM subjects (95±3.1) compared to the Non-GDM subjects 
(75.2±7.1),(p<0.013).The Mean blood pressure (mm of Hz, M±SD) also showed 
significantly higher in GDM subjects (95.2±7.8) compared to the Non-GDM subjects 
(88.4±1.2),(p<0.041). 
 
 
 
Characteristic Non-GDM 
n(%) 
GDM 
n(%) 
P value 
Parity   
- Primi para 69(36.3) 17(23.3) 0.159 
- Multi para 121(63.7) 56(76.7) 
Types of delivery 
- Normal 99(52.1) 32(43.8) 0.308 
- C-section 91(47.9) 41(56.2) 
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 Table 3.3: The clinical characteristics of Non-GDM and GDM subjects (n=263). 
Characteristic Non-GDM GDM P value 
Age (yrs) 21.53±3.76 21.57±3.2 0.939 
BMI (kg/m2) 23.31±3.1 25.5±3.7 <0.001 
SBP (mm of Hz) 80±4.5 113.9±11.2 0.023 
DBP(mm of Hz) 75.2±7.1 95±3.1 0.013 
MBP 88.4±1.2 95.2±7.8 0.041 
Results are expressed as mean± SD and median (range), n= number of subjects. 
HTN=Hypertension, BMI=Body Mass Index, WHR=Waist hip ratio, SBP=Systolic 
Blood pressure, DBP=Diastolic Blood Pressure MBP=Mean Blood pressure 
3.6 Glycemic and Lipidemic status of study participants 
Table 3.4 represents the biochemical characteristics of Non-GDM  and GDM subjects. 
The S Fasting glucose value (mmol/l, M±SD) showed significantly higher in GDM 
subjects (7.1±1.9) compare to the Non-GDM subjects (4.3±0.53), (p<0.001). The S 2 hr 
after glucose value (mmol/l, M±SD) showed significantly higher in GDM subjects 
(6.3±0.56) compare to the Non-GDM subjects (11.43±2.4), (p<0.001).The S TG (mg/dl 
,M±SD) showed significantly higher in GDM subjects (187.2±72.7) compare to the 
Non-GDM subjects (243.4±7.7), (p<0.012).The S Chol (mg/dl, M±SD) showed 
significantly higher in GDM subjects (118±4.3) compare to the Non-GDM subjects 
(208±1.2), (p<0.045). The S HDL-Cholesterol (mg/dl ,M±SD) and LDL-Cholesterol 
(mg/dl ,M±SD) showed no significant difference between GDM and Non-GDM 
subjects.  The S Creatinine (mg/dl, M±SD) showed significantly higher in GDM 
subjects (0.69±0.28) compare to the Non-GDM subjects (0.79±0.13),(p<0.001).The S 
Albumine (mg/dl, M±SD) showed significantly higher in GDM subjects (27.6±4.5) 
compare to the Non-GDM subjects (27.1±2.3), (p<0.001). 
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Table 3.4: The Glycemic and Lipidemic status of Non-GDM and GDM subjects 
Characteristic Non-GDM GDM P value 
S Fasting glucose value (mmol/l) 4.3±0.53 7.1±1.9 0.001 
S 2 hr after glucose value (mmol/l) 6.3±0.56 11.43±2.4 0.001 
S TG (mg/dl) 187.2±72.7 243.4±7.7 0.012 
S Chol (mg/dl) 118±4.3 208±1.2 0.045 
S HDL-Cholesterol (mg/dl) 43.3±10.9 33.3±5.9 0.451 
LDL-Cholesterol(mg/dl) 126.9±32.2 211.9±2.2 0.065 
S Creatinine (mg/dl) 0.69±0.28 0.79±0.13 0.001 
S Albumine (mg/dl) 27.6±4.5 27.1±2.3 0.001 
 
Results are expressed as Mean± SD. n= number of subjects. S TG=Serum Tri-
Glyceride, T Chol=Total Cholesterol, HDL=High Density Lipoprotein, LDL=Low 
Density Lipoprotein. 
 
3.7 Arsenic status in study participants  
Table 3.5 showed arsenic level in water in non-GDM and GDM subjects. Water arsenic 
level was significantly higher in the GDM as compared to the Non-GDM group [WAs, 
µg/l, median (range), 62(34-354) versus 3.6 (1.02-99), p<0.001].Urine arsenic level was 
also significantly higher in the GDM as compared to the Non-GDM group [U-As, µg/L, 
median (range), 60 (1.9–248) versus 2.21(1.31-89), p<0.001]. 
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  Table 3.5: Arsenic status in  Non-GDM and GDM subjects (n=263) 
Characteristic Non-GDM GDM P value 
Water Arsenic level (µg/L) 2.32±1.98 
3.6 
(1.02-99) 
14.8±1.98 
62 
(34-354) 
<0.001 
U-As (µg/L)  2.21 
(1.31-89) 
60  
(1.9–248) 
<0.001 
  
The results express mean±SD and median (range) where as applicable. Test of the 
significance level p<0.5 and analyzed by independents ‘t’ test. W-As Water arsenic 
level; U-As=Urinary arsenic level. 
 
3.8 Odds ratio of arsenic exposure in the study participants 
Table 3.6 showed odds ratio of water arsenic exposure in non-GDM and GDM subjects. 
The GDM subjects showed that 100 % subjects were high in Arsenic exposure and non-
GDM showed 45% High exposure. The Odds ratio with CI also support that 1.7 (1.502-
1.925) almost 2 times chance of developing gestational diabetes.  
 
Table 3.6: The odds ratio of arsenic exposure in GDM and Non-GDM subjects 
 
Characteristic Non-GDM GDM P value Odds ratio 
95% CI 
Low Arsenic exposure 104(54.7%) 0(0%)  
<0.001 
1.7 
(1.502-1.925) High Arsenic exposure 86(45.3%) 73(100%) 
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The result were express as number and percentages, n(%) and odds ratio, the 
significance level were analyzed by chi X2 test. Odds ratio represent the chance of 
happening disease. Arsenic exposure categorize by cut-off value, >10ug/L. 
3.9 Anthropometric measurement of Neonatal of the study subjects: Table-7 
Table 3.7 represents the anthropometric measurement of Neonatal of the study subjects. 
The fetal weight (Kg,M±SD) were  significantly higher in GDM subjects (3.8±1.02) 
compared to the Non-GDM subjects (3.03±0.27), (p=0.001). APGARScore of the 
neonates from GDM mothers was significantly lower compared to the neonates from 
Non-GDM mothers (APGER Score, M±SD, 4.7±0.8 vs 6.4±0.67, p<0.001).   
 
Table 3.7: The Anthropometric measurement of Neonatal of the study subjects 
Characteristic Non-GDM GDM P value 
Fetal Wt (gm) 2048 
(729-3000) 
2470 
(850-3200) 
0.620 
Fetal Wt (Kg) 3.03±0.27 3.8±1.02 0.001 
Apgar Score (in 5 minutes)  6.4±0.67 
7(6-8) 
4.7±0.8 
5(4-8) 
<0.001 
 
The results express mean±SD and median (range) where as applicable. Test of the 
significance level p<0.5 and analyzed by independent‘t’ test. 
 
3.10 Odds ratio of APGAR score in neonates of the study participants 
Table 3.8 showed odds ratio of APGAR score in non-GDM and GDM subjects. The 
GDM subjects showed 31.5% Apgar score and non-GDM showed 46.3% Apgar score. 
The Odds ratio with CI also support 5.033 (0.301-5.033) that almost 5 times chance of 
happening adverse effect of neonate of a GDM mother on later life.   
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Table 3.8: The odds ratio of APGAR score in neonates of the study subjects 
Characteristic Non-GDM GDM P value 95% CI odds 
ratio 
Low APGER score <7 102(53.7) 50(68.5) 
 
 0.029 
 
5.033 (0.301-
5.033) High APGER score >7 88(46.3) 23(31.5) 
 
The result were express as number and percentages, n(%) and odds ratio, the 
significance level were analyzed by chi X2 test. Odds ratio represent the chance of 
happening disease. Low APGAR score were categorize by cut-off value, >7 in 5 minits. 
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3.11 Correlation between Water arsenic Level and 2 hr after blood glucose value in 
GDM subjects. 
 
Figure 3.3: The Correlation between Water arsenic Level and 2 hr after blood 
glucose value in GDM subjects. 
Figure 3.3 represents that correlation between water arsenic level and 2 hr after blood 
glucose value inGDM subjects.This diagram showed that water level and blood glucose 
level are significant positively co-related with each other (r=0.429;p=<0.001). 
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3.12 Correlation of Water arsenic Level and 2 hr after blood glucose value in Non-
GDM subjects
 
Figure 3.4: The Correlation of Water arsenic Level and 2 hr after blood glucose 
value in Non-GDM subjects. 
 
This curve  showed no correlation between water arsenic level and blood glucose level 
(r=0., p=0.) in Non GDM subjects. 
 
 
 
 
r=0.429 
p<0.001 
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3.13 Correlation between Water arsenic Level and Urinary total arsenic level in 
GDM subjects
  
 
Figure 3.5: The Correlation between Water arsenic Level and Urinary total 
arsenic level in GDM subjects. 
 
Figure 3.5 represents that correlation between water arsenic level and Urinary total 
arsenic level in GDM subjects. This diagram showed that water level and blood glucose 
level are significant positively co-related with each other (r=0.234;p=<0.001). 
 
 
r=0.234; 
p<0.001 
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3.14  Correlation of Water arsenic Level and Low Apgar score in GDM subjects
 
 
Figure 3.6: The Correlation of Water arsenic Level and Low Apgar score in GDM 
subjects. 
Figure 3.6 represents that correlation between water arsenic level and low ApgarScore. 
This curve estimated that, the water arsenic level and Apgar score are negatively 
correlated with each other, when arsenic level is increased then Apgar score is 
decreased (r=0.233; p<0.041). 
 
 
 
 
r=-0.233 
p<0.041 
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3.15 Correlation of Water arsenic Level and Low Apgar score in Non-GDM 
subjects 
 
 
 
 
Figure 3.7: The Correlation of Water arsenic Level and Low Apgar score in Non-
GDM subjects. 
Figure 3.7 showed that correlation between water arsenic level and low Apgar score in 
Non-GDM subjects.This diagram showed no significant correlation between water 
arsenic level and Apgar score. 
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4. DISCUSSION 
 
Arsenic exposure is a well-recognized public health problem; millions of people world-
wide are potentially exposed inorganic arsenic from drinking water contaminated by 
naturally occurring sources (Tchounwou et al, 1999). Chronic exposure to arsenic is 
associated with a number of adverse health effects (Yoshida et al, 2004). 
 
Suggestive evidence links chronic exposure to high arsenic levels in drinking water with 
increased diabetes risk in Taiwan and Bangladesh. Methodologic problems, however, 
limit the causal interpretation of this association. The use of average drinking water and 
the lack of individual measures of arsenic possibly lead to underestimate the exposure 
(Navas acien, 2008). 
 
Although the present cross-sectional study was designed with exploration of arsenic 
contamination and associated health effects (maternal and neonatal) as its primary 
objectives, it gives an idea about the proportion of pregnant women converting to GDM 
in a tertiary hospital setup. Out of 263 pregnant women followed up from third trimester 
up to delivery 73 (28%) developed GDM. Prevalence of GDM up to 17% has been 
reported in a population based study in India (Seshiah et al, 2008); thus the present 
prevalence rate is much higher than that in the general population. The subjects in the 
present study, however, were collected from the Department of Gynecology and 
Obstetrics in few tertiary hospitals where a higher prevalence of GDM is expected. 
Large scale population based studies are required to find out a more accurate account of 
the conversion to GDM in general population.  
Environmental exposure to arsenic may result in abnormal glucose metabolism which, 
in turn, increases the risk of developing diabetes, through several plausible mechanisms 
(Longnecker and Daniels, 2001). Arsenic is a known endocrine disruptor (Tseng, 2004) 
and may disrupt the glucocorticoid receptor (Kaltreider et al, 2001), which regulates a 
wide range of biological processes in humans including insulin sensitivity. It is also 
possible that presence of diabetes or prediabetic conditions alter arsenic metabolism in 
such a way as to cause higher levels in the body. However, experimental evidence 
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suggest that oxidative stress and insulin resistance can be induced by arsenic, 
suggesting a biological plausibility to arsenic-induced diabetes (Tseng et al, 2004).  
 
The present data shows an urinary total arsenic concentration of 60 (1.9–248) µg /l 
[(95% CI, 1.7 (1.502-1.925)]. NHANES (National Health and Nutrition Examination 
Survey) data suggest almost similar findings; as per its report the average urinary total 
arsenic concentration is 8.30 µg/L (95% CI, 7.19–9.57) (Caldwell et al, 2008). Using 
data from the same nationally representative cross-sectional survey of the U.S. 
population ,Navas-Acien and colleagues (2008) found that participants with type 2 
diabetes had a 26% higher level of total arsenic (95% CI, 2.0–56.0) and the OR for type 
2 diabetes comparing participants at the 80th versus the 20th percentiles was 3.58 for 
the level of urinary total arsenic (95% CI, 1.18–10.83).  Saldana (2007) has also shown 
an association of environmental exposure (agricultural pesticides) and increased risk of 
GDM among wives of licensed pesticide applicators. Another study, used sensitive 
laboratory biomarkers of both the exposure (arsenic) and outcome (plasma glucose). 
Levels of total arsenic exposure (measured in maternal blood and hair) in their study 
were higher than reported background levels of arsenic in unexposed individuals 
(ATSDR 2007). Their results taken together suggest that, a significant portion of US 
women of childbearing age may be at risk for GDM due to environmental exposures 
such as arsenic. 
 
In this cross-sectional study, daily arsenic contaminated GDM women were compared 
with Non-GDM women. Women diagnosed with diabetes in third trimester of 
pregnancy, differed already during these pregnancies in several parameters (Serum Tri-
Glyceride, Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, 
creatinine, albumin etc) during their pregnancies. The mothers who were exposed with 
arsenic during pregnancy, had more complications, such as development of diabetes 
later. They also had caesarean delivery more often; (31.3%) delivered by caesarean 
section compared to (68.7%) women who did not develop diabetes.  
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Among this population of pregnant women with relatively high exposure, arsenic con-
centration was associated with impaired glucose tolerance during pregnancy and there-
fore may be associated with increased risk of GDM. Women in the highest quartile of 
urine arsenic exposure had almost two times 1.7(1.502-1.925) higher odds of impaired 
GTT than women in the lowest quartile of exposure, and there was a statistically 
significant (P<0.001) trend in risk of impaired GTT by increasing quartile of exposure. 
On the other hand, a study from Korea did find an association between arsenic exposure 
and diabetes in people exposed to normal, background exposure levels of arsenic, 
especially women (Kim and Lee, 2011).In a recent study it was shown that people from 
rural communities in the US with high rates of diabetes, arsenic was associated with 
poorer diabetes control (a higher HbA1c) in people with diabetes (Gribble et al, 2012). 
Vahter et al (2006), claimed that higher arsenic concentration is associated with 
gestational diabetes mellitus and pregnancy complications. 
 
The Apgar score system used to estimate the probability of survival of the infant 
(Metzger et al, 2002; HAPO study, 2009) and to appraise the need for resuscitation 
(Aberg et al, 2002). An additional score obtained at five minutes of age gained 
universal acceptance after the report from the Collaborative Perinatal Project which 
showed a stronger relation between the five-minute score and neonatal mortality than 
the one-minute score (Crowther et al, 2005). However, it has been suggested that the 
Apgar score is antiquated and that its predictive value has been considerably weakened 
by the institution of prompt and effective neonatal care.  
 
The relationship between five-minute Apgar scores and infant survival analysis 
indicates that the Apgar score is not only useful for neonatal period and term infants as 
it was 50 years ago, but also meaningful for post-neonatal period and preterm infants. 
Hence, Apgar score could still be a good and convenient predictor of infant death. 
Apgar scores are used as an indicator of the well being of the newborn.  
 
The Apgar scores of the infants were lower among the women with GDM or later Type 
2 diabetes compared to women without diabetes. In the multivariate analysis calculating 
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risk for low Apgar scores in the whole cohort, pre pregnancy weight of the mother, 
GDM or later Type 2 diabetes, low birth weight and short gestational length were 
significant risk factors at 5 min but for low Apgar at 10 min only low birth weight and 
short gestational length were significant. This indicates that prematurity for any reason 
in general is the dominating condition behind sustained low Apgar score.  
 
There was a significantly (P<0.001) higher value of drinking water arsenic level 
(14.8±1.98) in GDM compared to Non-GDM (2.32±4.34) subjects in the third 
trimesters. It seems that the involvement is indirect as there was significant correlation 
of fasting or 2-hr blood glucose level (11.43±2.4 vs 6.3±0.56; p<0.001) with higher 
urine arsenic level in GDM. Their newborns were heavier despite a shorter gestational 
length and had significantly lower Apgar scores (5.7±0.8), which was indicating poor 
neonatal outcome.  The cut-off value is categorize 75th percentile <7 and odds ratio of 
APGAR score is (CI, 5.033 (0.301-5.033) which shows that chance of risk is almost 5 
times higher. 
 
In a recent study on Bengali population with much higher levels of exposure, blood 
arsenic levels were highly correlated with creatinine-adjusted urinary concentrations (r 
= 0.85) and with drinking-water arsenic concentration (r = 0.75) (Hall et al. 2006). In 
our findings, on Pearson’s correlation analysis in GDM subjects, WAs levels were 
found to have a significant positive correlation with both fasting and postprandial serum 
glucose (r=0.638;p=<0.05) and the urinary arsenic level (r=0.234;p<0.001) and also the 
low APGER Score of the neonates were found to have a significant negative correlation 
with serum glucose (r=0.233; p=0.041). 
 
The limitation of the present study was that water and urine sample collected at the time 
of third trimester or before delivery as a biomarker of arsenic exposure, which was mea-
sured at least 24 to 28 weeks of pregnancy. That may have a strong association with 
outcome. Another limitation is that arsenic exposure measuring sample were blood and 
hair and nail were not analyzed. Because arsenic binds to the sulfhydryl groups in 
keratin, the primary component in hair and nails, this is where the highest levels of 
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arsenic tend to be found (Liu et al, 2008). Therefore, studies of chronic arsenic 
exposure often use hair or nails as biomarkers of cumulative exposure. Although nails 
or hair may best represent cumulative exposure, keratin-bound arsenic is isolated from 
the body’s further metabolic processes and may be less biologically active than blood 
arsenic. Because of these differences in biomarkers of arsenic exposure, hair was used 
in a subset of women with samples available, to provide estimation of long-term 
exposures, with every 1 cm of hair representing each month of prior exposure (Kurttio 
et al, 1998). It was believed that due to chronic exposures, arsenic level in circulation 
reaches a steady-state level and it may better reflect an individual’s total intake of 
internal arsenic (Hall et al, 2006).  
 
In summary, GDM is a major potential complication of pregnancy associated with 
negative health effects for both the mother and infant. Understanding the effects of 
environmental exposure on impaired glucose tolerance during pregnancy may have 
substantial public health importance beyond the direct effects on GDM. Studies are 
needed to investigate environmental, behavioral and biological factors that may 
contribute to a risk of development and progression of diabetes and its related maternal 
and neonatal complications. Such studies should incorporate culturally specific lifestyle 
factors into treatment and prevention strategies to reduce risk across racial, ethnic, and 
socioeconomic groups. Future research in this area will be important for understanding 
whether different pathophysiologic mechanisms or risk factors are responsible for 
increased diabetes risk and especially in children. Genetic background may also play a 
role in the susceptibility of individuals to the effects of arsenic. For example, a study 
from parts of Mexico with historically high levels of arsenic exposure found that people 
who had certain genes are more likely to develop diabetes when exposed to arsenic 
(Drobna et al, 2012). In addition, better understanding of modifiable risk factors for 
GDM such as diet (antioxidant rich food) and activity patterns (such as breast feeding 
practices) related to environmental exposures may lead to efforts at primary prevention.  
 
The above findings imply that arsenic contamination may play a role in glucose 
intolerance and may be associated with an increased risk of GDM; it may contribute to 
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lower apger score in babies. Our results probably represent more than a potential causal 
association between arsenic and GDM; it may also provide clues to long-observed 
health disparities that might have prevented public health interventions.  
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                                                          APPENDIX- I 
Data Collection Sheet 
ID:       Date 
Institution: 
Particulars of the patients:- 
Name: 
Age: 
Address 
a) Present : 
Telephone No:  
b) Permanent: 
Contact person address: 
Telephone no: 
Education:  1□Masters 2□Graduate 3□ HSC 4□SSC  5□Primary
     6 □Illiterate 
Occupation: 1□Housewife 2□Service 3□Students 4□Others  
Location:     1□Urban   2□Semi urban     3□Rural 
 
Family Members:  
Monthly family income:  
Menstrual history:  MP/MC  
        L.M.P   
          E.D.D 
Obstetrical history:         Para          
        Gravida 
         ALC  
Risk factors:- 
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Obesity Yes1/No0 
Positive history of diabetes (sibs/parents) Yes1/No0 
H/O delivery of large infant (>400 gm) Yes1/No0 
H/O still birth Yes1/No0 
/O prematurity Yes1/No0 
H/O unexplained neonatal death Yes1/No0 
H/O pre eclampsia Yes1/No0 
H/O traumatic delivery e associated neurological disorder in the 
infant 
Yes1/No0 
Poor reproductive history (>3 spontaneous abortions in the 1st or 
2nd trimester) 
Yes1/No0 
Chronic hypertension Yes1/No0 
 
Physical / Clinical Examination (Mother): 
Observations 1st visit 
Date………… 
2nd visit 
Date…….. 
Height   
Weight   
BMI   
BP   
Height of Uterus   
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Biochemical Investigation : 
Observations 1st visit 
Date………… 
2nd visit 
Date…….. 
Fasting blood glucose (mmol/l)   
Blood  glucose 2 hr after 75 gm of glucose 
(mmol/l) 
  
Serum TG (mg/dl)   
Serum T-chol (mg/dl)   
Serum HDL (mg/dl)   
Serum LDL (mg/dl)   
 
 
Physical / Clinical Examination (Neonates): 
Observations 1st visit 
Date………… 
Length  
Weight  
APGAR score at 5 minits  
Activity (muscle tone)  
                    Active 2  
                   Arms and legs flexed 1  
                   Absent 0  
Pulse  
                 >100 bpm 2  
                  <100 bpm 1  
                    Absent 0  
Grimace (reflex irritability)  
                    Sneezes, coughs, pulls away 2  
                    Grimaces 1  
                   No response 0  
Appearance (skin color)  
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                    Normal over entire body 2  
                    Normal except extremities 1  
                    Cyanotic or pale all over 0  
Respirations  
                   Good, crying 2  
                    Slow, irregular 1  
                    Absent 0  
 
       --------------------------------- 
Interviewer signature 
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APPENDIX- II 
Estimation of plasma blood glucose (Randox laboratories, UK). 
Plasma glucose was estimated by enzymatic colorimetric  (GOD-PAP) method  
Principle (Barham, Trinder, 1972)  
Glucose is determined after enzymatic oxidation in the presence of glucose 
oxidase. The hydrogen peroxide formed reacts, under catalysis of peroxidase, 
with phenol and 4-aminophenazone to form a red violet quinoneimine dye as 
indicator. 
Glucose + H2O ⎯⎯⎯⎯ →⎯Oxidase
eGlucos
Gluconic acid + H2O2 
2H2O2 + 4-aminophenazone + phenol ⎯⎯⎯⎯⎯ →⎯Peroxidase Quinoneimine + 4H2O 
Reagents 
Contents Initial concentration of solution 
Buffer  
Phosphate Buffer 0.1 mol/l, pH 7.0 
Phenol 11 mol/l 
GOD-PAP Reagent  
4-aminophenazone 0.77 mmol/l 
Glucose oxidase ≥1.5 kU/l 
Peroxidase ≥1.5 kU/l 
Standard  
Glucose 5.55 mmol/l (100 mg/dl) 
 
Additional Reagent 
Uranyl Acetate 0.16% cat NO DP 647 2x 500 ml 
Materials required  
Microcentrifuge tube 
Micropipettes and pipettes with disposable tips  
AUTOLAB (Analyzer Medical system, Rome, Italy) 
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Procedure 
Procedure for glucose GOD-PAP assay without deproteinisation. The 
instrument was calibrated before estimation. 
Plasma and reagent were taken in specific cup. They were arranged serially 
into the Auto lab Analyzer (Analyzer Medical system, Rome, Italy). The Auto 
lab was programmed for the estimation of glucose and allowed to run with 
following procedure: 
5 µl sample and 500 µl reagent were mixed and incubated at 370 C for 10 
minutes. The reaction occurred in reaction cell or cup. The absorbance of the 
sample and the standard against the reagent blank were measured at 500 nm 
within 60 minutes. 
Calculation of result 
Optical densities or absorbances were fed into a computer and calculation 
was done using the software program. Values for the unknown samples were 
calculated by extrapolating the absorbance for the standard using following 
formula.  
Glucose concentration (mmol/l) =
dardS
Sample
A
A
tan
×5.5 
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APPENDIX- III 
Estimation of serum total cholesterol (Randox laboratories, UK)  
Total cholesterol was measured by enzymatic endpoint method (cholesterol 
Oxidase/Peroxidase) method in auto analyzer (Analyzer Medical System, 
Rome, Italy) using reagent of Randox laboratories, UK.  
Principle (Trinder, 1988) 
The cholesterol was determined after enzymatic hydrolysis and oxidation. 
The indicator quinoneimine is formed from hydrogen peroxide and 4-
aminoantiphyrine in the presence of phenol and peroxidase.  
Cholesterolester + H2O ⎯⎯⎯⎯⎯ →⎯Esterase
lCholestero
Cholesterol + fatty acids 
Cholesterol + O2 ⎯⎯⎯⎯⎯ →⎯Oxidase
lCholestero
Cholestene- 3-one + H2 O2 
2 H2 O2 +phenol+4-aminoantiphyrine ⎯⎯⎯⎯⎯ →⎯Peroxidase  quinoneimine + H2 O 
Reagent composition 
Contents Initial Concentration of Solution 
Reagent  
4-Aminoantipyrine 0.30 mmol/l 
Phenol 6 mmol/l 
Peroxidase >  0.5 U/ml 
Cholesterol esterase >  0.15 U/ml 
Cholesterol oxides >  0.1 U/ml 
Pipes Buffer 80 mmol/l; pH 6.8 
Standard 5.17 mmol/l (200 mg/dl) 
Materials 
 
Microcentrifuge tube 
 
Micropipettes and pipettes 
 
Disposable tips 
  Page xv 
 
 
AUTOLAB (Analyzer Medical system, Rome, Italy) 
 
Procedure 
 
Plasma and reagents were taken in specific cup or cell. They were arranged 
serially. Then ID number for each test was entered in the AUTOLAB.  5 µl 
sample and 500 µl reagent were mixed and incubated at 370C for 5 minutes 
within the Auto lab. The reaction occurred in reaction cell or cup. The 
absorbance of the sample and the standard against the reagent blank were 
measured at 500 nm within 60 minutes. 
Calculation of result 
Concentration of cholesterol in sample was calculated by using software 
program with the following formula. 
Cholesterol concentration (mg/dl) = 
dardS
Sample
A
A
tan
 ×  concentration of standard.    
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APPENDIX- IV 
Estimation of plasma triglycerides  
Plasma triglyceride was measured by enzymatic colorimetric (GPO-PAP) 
method in auto analyzer (Analyzer Medical System, Rome, Italy) using 
reagent of Randox laboratories, UK. 
Principle  
The triglyceride is determined after enzymatic hydrolysis with lipases. The 
indicator is a quinoneimine formed from hydrogen- peroxide, 4- 
aminophenazone and 4-chlorophenol under the catalytic influence of 
peroxidase (Trinder 1969).  
Triglyceride +H2O ⎯⎯⎯ →⎯Lipase glycerol + fatty acids  
Glycerol + ATP ⎯⎯⎯⎯ →⎯Kinase
Glycerol
glycerol-3-phosphate + ADP 
Glycerol-3-phosphate +O2 ⎯⎯⎯⎯ →⎯Oxidase
Phosphate
Glycerol
dihydroxy acetone phosphate + 
H2O2 
2H2O2 + 4-aminophenazone +4- chlorophenol ⎯⎯⎯⎯⎯ →⎯Peroxidase quinoneimine + 
                                                                                                     HCl +4 H2O 
Reagents 
Contents Concentrations in the Test 
Buffer 
      Pipes Buffer 
     4-choloro-phenol 
     Magnesium-ions 
 
40 mmol/l, pH 7.6 
5.5 mmol/l 
17.5 mmol/l 
2.  Enzyme Reagent 
    4-aminophenazone 
    ATP 
    Lipases 
    Glycerol-3-phosphate oxidase 
    Peroxidase 
 
mmol/l 
1.0 mmol/l 
>150 U/ml 
1.5 U/ml 
0.5 U/ml 
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3.  Standard 2.29 mmol/l (200 mg/dl) 
Materials 
Micropipettes and pipettes 
Disposable tips 
AUTOLAB (Analyzer medical system, Rome, Italy) 
Procedure 
Plasma and reagents were taken in specific cup or cell. They were arranged 
serially. Then ID number for each test was entered in the AUTOLAB. 5 µl 
sample and 500 µl reagent were mixed and incubated at 370C for 5 minutes 
within the AUTOLAB. 
The reaction occurred in reaction cell. The absorbance of the sample and the 
standard against the reagent blank were measured at 500 nm within 60 
minutes. 
Calculation of result 
Triglyceride concentration was calculated by using software program in 
AUTOLAB with the following formula. 
Triglyceride concentration (mg/dl) = 
dardS
Sample
A
A
tan
×Concentration of the 
standard. 
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Appendix- V 
Estimation of serum high density lipoprotein (HDL)  
Plasma high-density lipoprotein (HDL) was measured by enzymatic colorimetric 
(cholesterol CHOD-PAP) method in auto analyzer (Analyzer Medical System, Rome, 
Italy) (Friedewald WT, 1972) 
Principle   
HDL (High Density Lipoproteins) are separated from chylomicrons, VLDL 
(very low density lipoproteins) and LDL (Low density lipoproteins) by the 
addition of a precipitating reagent (phosphotungstic acid-magnesium 
chloride) to serum or plasma. After centrifugation, the cholesterol contents of 
HDL fraction which remains in the supernatant are determined by the 
enzymatic colorimetric method using CHOD- PAP. 
Reagent composition 
Contents 
Buffer 
Enzymes 
Standard 50 mg/dl (1.29 mmol/l) 
Materials 
Microcentrifuge tube, Micropipettes and pipettes 
Disposable tips 
AUTOLAB 
Procedure     
Samples (200 ml) and precipitating reagents (500 µl) were taken in a microcentrifuge 
tube. Then it was mixed and allowed to sit for 10 minutes at room temperature. Then 
it was centrifuged at 4000 rpm for 10 minutes. 
The supernatant was used as sample for determination of cholesterol content by the 
CHOD-PAP method. The sample and reagents were taken in specific cup or cell. 
They were arranged serially then ID number for test was entered in the AUTOLAB. 
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Then 5 µl sample and 500 µl reagent were mixed and incubated at 370C for 5 minutes 
within the AUTOLAB. The reaction occurred in reaction cell. The absorbance of the 
sample and the standard against the reagent blank were measured at 500 nm within 
60 minutes. 
Calculation of result 
Concentration was calculated by using software program. 
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Appendix- VI 
Estimation of LDL cholesterol level in serum  
 
LDL cholesterol level in serum was calculated by using by Friedewald 
formula (Friedewald WT. 1972) 
Formula  
LDL cholesterol =Total cholesterol– (HDL Cholesterol + x
5
1
 Triglyceride) 
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Appendix- VII 
ARSENIC ESTIMATION SPECTROPHOTOMETER  
Experimental Procedure 
Apparatus 
A Secomam Anthelie NUA 002 UV-VIS spectro- photometer with 1 cm quartz 
cell was used for the absorbance measurements and a WTW pH 330, pH 
meter was used for pH measurements. 
Reagents 
All chemicals used were of analytical grade and distilled water was used for 
dilution of reagents and samples. Standard arsenic (III) stock solution (1000 
µg mL-1) was prepared by dissolving 0.1732 g of NaAsO2 in 100 mL of water. 
Working standard solution was prepared by dilution of stock solution. 
Hydrochloric acid, 0.4 M, potassium iodate, 2%, sodium acetate, 2 M were 
used. A 0.05% solution of variamine blue was prepared by dissolving 0.05 g of 
variamine blue in 25 mL of ethanol and making up to 100 mL with distilled 
water. The solution was stored in an amber bottle. 
Method 
Preparation of calibration curve 
An aliquot of a sample solution containing 0.2-14 µg mL-1 of arsenic(III) was 
transferred into a series of 10 mL calibrated flasks. Then, potassium iodate 
(2%, 1 mL) and hydrochloric acid (0.4 M, 1 mL) were added and mixture was 
gently shaken. This was followed by addition of variamine blue (0.05%, 1 mL) 
and 2 mL of 2 M sodium acetate solution. The solution was kept for 5 min and 
made up to the mark with distilled water. The absorbance of the coloured 
species was measured at 556 nm against the corresponding reagent blank. 
Determination of arsenic in urine and serum 
Arsenic is reported to be present in trace amounts in normal urine and serum 
27(Patty 1963). If a person is affected by arsenic poisoning the amount of 
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arsenic in urine and serum increases. To check the validity of the method 
synthetic samples were prepared by adding known amounts of arsenic to 
serum and urine samples. The samples were deprotonised with 
trichloroacetic acid and filtered. Aliquots were then analyzed for arsenic by 
the proposed and reported methods 29(Pillai,Sunita & Gupta;2000). 
Determination of arsenic in hair and nails 
People drinking arsenic contaminated water have been reported to have 
high arsenic in their hair and nails. About 0.5 to 1.0 g of hair and nail samples 
were placed in a tube containing 10 mL of nitric acid. The tube was closed and 
heated on a hot plate at 100°C for 5 min. After 24 h the lid was opened and 1 
mL of concentrated nitric acid was added and evaporated at 100°C until 1 mL 
of solution remained. Few drops of 10% KI were added to convert As(V) to 
As(III). The presence of any excess of iodine, indicated by light brown colour 
was destroyed by adding few drops of ascorbic acid 28(Sandell 1959). The 
sample was cooled, diluted to 5 mL and analyzed by the proposed and also 
by reported method29(Pillai,Sunita & Gupta;2000). 
Determination of arsenic in plant material 
A sample of plant material (5 g) was digested with 10 mL of HNO3 for 
about 20 min. After cooling, 1 mL of perchloric acid was added and heating 
was continued for about another 10 min. As(V) if any, is reduced to As(III) by 
the process described above. The solution was transferred to a 25 mL 
volumetric flask and diluted to volume with water. Aliquots of the sample 
were analysed by the recommended procedure and also by the reported 
method 29(Pillai,Sunita & Gupta;2000). 
Determination of arsenic in soil 
A known weight (1 g) of a soil sludge sample was placed in a 50 mL beaker 
and extracted 4 times with a 5 mL portion of concentrated HCl. The extract 
was boiled for about 30 min. As(V) if any, is reduced to As(III). The solution 
was cooled and diluted to 25 mL with distilled water. Aliquots of the sample 
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were analysed by the recommended method and also by the reported method 
29(Pillai,Sunita & Gupta;2000).. 
 
Determination of arsenic in natural and polluted water 
Water samples from a river receiving effluent of steel plant and fertilizer 
factory were collected in polyethylene bottles and filtered through Whatman 
41 filter paper. As(V) if any, is reduced to As(III) by the process described. 
Arsenic content was determined directly according to the recommended 
method and also by the reported method 29(Pillai,Sunita & Gupta;2000). 
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 APPENDICES 
                                      
 
                                                          APPENDIX- I 
Data Collection Sheet 
ID:       Date 
Institution: 
Particulars of the patients:- 
Name: 
Age: 
Address 
a) Present : 
Telephone No:  
b) Permanent: 
Contact person address: 
Telephone no: 
Education:  1□Masters 2□Graduate 3□ HSC 4□SSC  5□Primary
     6 □Illiterate 
Occupation: 1□Housewife 2□Service 3□Students 4□Others  
Location:     1□Urban   2□Semi urban     3□Rural 
 
Family Members:  
Monthly family income:  
Menstrual history:  MP/MC  
        L.M.P   
          E.D.D 
Obstetrical history:         Para          
        Gravida 
         ALC  
Risk factors:- 
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Obesity Yes1/No0 
Positive history of diabetes (sibs/parents) Yes1/No0 
H/O delivery of large infant (>400 gm) Yes1/No0 
H/O still birth Yes1/No0 
/O prematurity Yes1/No0 
H/O unexplained neonatal death Yes1/No0 
H/O pre eclampsia Yes1/No0 
H/O traumatic delivery e associated neurological disorder in the 
infant 
Yes1/No0 
Poor reproductive history (>3 spontaneous abortions in the 1st or 
2nd trimester) 
Yes1/No0 
Chronic hypertension Yes1/No0 
 
Physical / Clinical Examination (Mother): 
Observations 1st visit 
Date………… 
2nd visit 
Date…….. 
Height   
Weight   
BMI   
BP   
Height of Uterus   
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Biochemical Investigation : 
Observations 1st visit 
Date………… 
2nd visit 
Date…….. 
Fasting blood glucose (mmol/l)   
Blood  glucose 2 hr after 75 gm of glucose 
(mmol/l) 
  
Serum TG (mg/dl)   
Serum T-chol (mg/dl)   
Serum HDL (mg/dl)   
Serum LDL (mg/dl)   
 
 
Physical / Clinical Examination (Neonates): 
Observations 1st visit 
Date………… 
Length  
Weight  
APGAR score at 5 minits  
Activity (muscle tone)  
                    Active 2  
                   Arms and legs flexed 1  
                   Absent 0  
Pulse  
                 >100 bpm 2  
                  <100 bpm 1  
                    Absent 0  
Grimace (reflex irritability)  
                    Sneezes, coughs, pulls away 2  
                    Grimaces 1  
                   No response 0  
Appearance (skin color)  
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                    Normal over entire body 2  
                    Normal except extremities 1  
                    Cyanotic or pale all over 0  
Respirations  
                   Good, crying 2  
                    Slow, irregular 1  
                    Absent 0  
 
       --------------------------------- 
Interviewer signature 
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APPENDIX- II 
Estimation of plasma blood glucose (Randox laboratories, UK). 
Plasma glucose was estimated by enzymatic colorimetric  (GOD-PAP) method  
Principle (Barham, Trinder, 1972)  
Glucose is determined after enzymatic oxidation in the presence of glucose 
oxidase. The hydrogen peroxide formed reacts, under catalysis of peroxidase, 
with phenol and 4-aminophenazone to form a red violet quinoneimine dye as 
indicator. 
Glucose + H2O ⎯⎯⎯⎯ →⎯Oxidase
eGlucos
Gluconic acid + H2O2 
2H2O2 + 4-aminophenazone + phenol ⎯⎯⎯⎯⎯ →⎯Peroxidase Quinoneimine + 4H2O 
Reagents 
Contents Initial concentration of solution 
Buffer  
Phosphate Buffer 0.1 mol/l, pH 7.0 
Phenol 11 mol/l 
GOD-PAP Reagent  
4-aminophenazone 0.77 mmol/l 
Glucose oxidase ≥1.5 kU/l 
Peroxidase ≥1.5 kU/l 
Standard  
Glucose 5.55 mmol/l (100 mg/dl) 
 
Additional Reagent 
Uranyl Acetate 0.16% cat NO DP 647 2x 500 ml 
Materials required  
Microcentrifuge tube 
Micropipettes and pipettes with disposable tips  
AUTOLAB (Analyzer Medical system, Rome, Italy) 
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Procedure 
Procedure for glucose GOD-PAP assay without deproteinisation. The 
instrument was calibrated before estimation. 
Plasma and reagent were taken in specific cup. They were arranged serially 
into the Auto lab Analyzer (Analyzer Medical system, Rome, Italy). The Auto 
lab was programmed for the estimation of glucose and allowed to run with 
following procedure: 
5 µl sample and 500 µl reagent were mixed and incubated at 370 C for 10 
minutes. The reaction occurred in reaction cell or cup. The absorbance of the 
sample and the standard against the reagent blank were measured at 500 nm 
within 60 minutes. 
Calculation of result 
Optical densities or absorbances were fed into a computer and calculation 
was done using the software program. Values for the unknown samples were 
calculated by extrapolating the absorbance for the standard using following 
formula.  
Glucose concentration (mmol/l) =
dardS
Sample
A
A
tan
×5.5 
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APPENDIX- III 
Estimation of serum total cholesterol (Randox laboratories, UK)  
Total cholesterol was measured by enzymatic endpoint method (cholesterol 
Oxidase/Peroxidase) method in auto analyzer (Analyzer Medical System, 
Rome, Italy) using reagent of Randox laboratories, UK.  
Principle (Trinder, 1988) 
The cholesterol was determined after enzymatic hydrolysis and oxidation. 
The indicator quinoneimine is formed from hydrogen peroxide and 4-
aminoantiphyrine in the presence of phenol and peroxidase.  
Cholesterolester + H2O ⎯⎯⎯⎯⎯ →⎯Esterase
lCholestero
Cholesterol + fatty acids 
Cholesterol + O2 ⎯⎯⎯⎯⎯ →⎯Oxidase
lCholestero
Cholestene- 3-one + H2 O2 
2 H2 O2 +phenol+4-aminoantiphyrine ⎯⎯⎯⎯⎯ →⎯Peroxidase  quinoneimine + H2 O 
Reagent composition 
Contents Initial Concentration of Solution 
Reagent  
4-Aminoantipyrine 0.30 mmol/l 
Phenol 6 mmol/l 
Peroxidase >  0.5 U/ml 
Cholesterol esterase >  0.15 U/ml 
Cholesterol oxides >  0.1 U/ml 
Pipes Buffer 80 mmol/l; pH 6.8 
Standard 5.17 mmol/l (200 mg/dl) 
Materials 
 
Microcentrifuge tube 
 
Micropipettes and pipettes 
 
Disposable tips 
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AUTOLAB (Analyzer Medical system, Rome, Italy) 
 
Procedure 
 
Plasma and reagents were taken in specific cup or cell. They were arranged 
serially. Then ID number for each test was entered in the AUTOLAB.  5 µl 
sample and 500 µl reagent were mixed and incubated at 370C for 5 minutes 
within the Auto lab. The reaction occurred in reaction cell or cup. The 
absorbance of the sample and the standard against the reagent blank were 
measured at 500 nm within 60 minutes. 
Calculation of result 
Concentration of cholesterol in sample was calculated by using software 
program with the following formula. 
Cholesterol concentration (mg/dl) = 
dardS
Sample
A
A
tan
 ×  concentration of standard.    
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APPENDIX- IV 
Estimation of plasma triglycerides  
Plasma triglyceride was measured by enzymatic colorimetric (GPO-PAP) 
method in auto analyzer (Analyzer Medical System, Rome, Italy) using 
reagent of Randox laboratories, UK. 
Principle  
The triglyceride is determined after enzymatic hydrolysis with lipases. The 
indicator is a quinoneimine formed from hydrogen- peroxide, 4- 
aminophenazone and 4-chlorophenol under the catalytic influence of 
peroxidase (Trinder 1969).  
Triglyceride +H2O ⎯⎯⎯ →⎯Lipase glycerol + fatty acids  
Glycerol + ATP ⎯⎯⎯⎯ →⎯Kinase
Glycerol
glycerol-3-phosphate + ADP 
Glycerol-3-phosphate +O2 ⎯⎯⎯⎯ →⎯Oxidase
Phosphate
Glycerol
dihydroxy acetone phosphate + 
H2O2 
2H2O2 + 4-aminophenazone +4- chlorophenol ⎯⎯⎯⎯⎯ →⎯Peroxidase quinoneimine + 
                                                                                                     HCl +4 H2O 
Reagents 
Contents Concentrations in the Test 
Buffer 
      Pipes Buffer 
     4-choloro-phenol 
     Magnesium-ions 
 
40 mmol/l, pH 7.6 
5.5 mmol/l 
17.5 mmol/l 
2.  Enzyme Reagent 
    4-aminophenazone 
    ATP 
    Lipases 
    Glycerol-3-phosphate oxidase 
    Peroxidase 
 
mmol/l 
1.0 mmol/l 
>150 U/ml 
1.5 U/ml 
0.5 U/ml 
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3.  Standard 2.29 mmol/l (200 mg/dl) 
Materials 
Micropipettes and pipettes 
Disposable tips 
AUTOLAB (Analyzer medical system, Rome, Italy) 
Procedure 
Plasma and reagents were taken in specific cup or cell. They were arranged 
serially. Then ID number for each test was entered in the AUTOLAB. 5 µl 
sample and 500 µl reagent were mixed and incubated at 370C for 5 minutes 
within the AUTOLAB. 
The reaction occurred in reaction cell. The absorbance of the sample and the 
standard against the reagent blank were measured at 500 nm within 60 
minutes. 
Calculation of result 
Triglyceride concentration was calculated by using software program in 
AUTOLAB with the following formula. 
Triglyceride concentration (mg/dl) = 
dardS
Sample
A
A
tan
×Concentration of the 
standard. 
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Appendix- V 
Estimation of serum high density lipoprotein (HDL)  
Plasma high-density lipoprotein (HDL) was measured by enzymatic colorimetric 
(cholesterol CHOD-PAP) method in auto analyzer (Analyzer Medical System, Rome, 
Italy) (Friedewald WT, 1972) 
Principle   
HDL (High Density Lipoproteins) are separated from chylomicrons, VLDL 
(very low density lipoproteins) and LDL (Low density lipoproteins) by the 
addition of a precipitating reagent (phosphotungstic acid-magnesium 
chloride) to serum or plasma. After centrifugation, the cholesterol contents of 
HDL fraction which remains in the supernatant are determined by the 
enzymatic colorimetric method using CHOD- PAP. 
Reagent composition 
Contents 
Buffer 
Enzymes 
Standard 50 mg/dl (1.29 mmol/l) 
Materials 
Microcentrifuge tube, Micropipettes and pipettes 
Disposable tips 
AUTOLAB 
Procedure     
Samples (200 ml) and precipitating reagents (500 µl) were taken in a microcentrifuge 
tube. Then it was mixed and allowed to sit for 10 minutes at room temperature. Then 
it was centrifuged at 4000 rpm for 10 minutes. 
The supernatant was used as sample for determination of cholesterol content by the 
CHOD-PAP method. The sample and reagents were taken in specific cup or cell. 
They were arranged serially then ID number for test was entered in the AUTOLAB. 
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Then 5 µl sample and 500 µl reagent were mixed and incubated at 370C for 5 minutes 
within the AUTOLAB. The reaction occurred in reaction cell. The absorbance of the 
sample and the standard against the reagent blank were measured at 500 nm within 
60 minutes. 
Calculation of result 
Concentration was calculated by using software program. 
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Appendix- VI 
Estimation of LDL cholesterol level in serum  
 
LDL cholesterol level in serum was calculated by using by Friedewald 
formula (Friedewald WT. 1972) 
Formula  
LDL cholesterol =Total cholesterol– (HDL Cholesterol + x
5
1
 Triglyceride) 
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Appendix- VII 
ARSENIC ESTIMATION SPECTROPHOTOMETER  
Experimental Procedure 
Apparatus 
A Secomam Anthelie NUA 002 UV-VIS spectro- photometer with 1 cm quartz 
cell was used for the absorbance measurements and a WTW pH 330, pH 
meter was used for pH measurements. 
Reagents 
All chemicals used were of analytical grade and distilled water was used for 
dilution of reagents and samples. Standard arsenic (III) stock solution (1000 
µg mL-1) was prepared by dissolving 0.1732 g of NaAsO2 in 100 mL of water. 
Working standard solution was prepared by dilution of stock solution. 
Hydrochloric acid, 0.4 M, potassium iodate, 2%, sodium acetate, 2 M were 
used. A 0.05% solution of variamine blue was prepared by dissolving 0.05 g of 
variamine blue in 25 mL of ethanol and making up to 100 mL with distilled 
water. The solution was stored in an amber bottle. 
Method 
Preparation of calibration curve 
An aliquot of a sample solution containing 0.2-14 µg mL-1 of arsenic(III) was 
transferred into a series of 10 mL calibrated flasks. Then, potassium iodate 
(2%, 1 mL) and hydrochloric acid (0.4 M, 1 mL) were added and mixture was 
gently shaken. This was followed by addition of variamine blue (0.05%, 1 mL) 
and 2 mL of 2 M sodium acetate solution. The solution was kept for 5 min and 
made up to the mark with distilled water. The absorbance of the coloured 
species was measured at 556 nm against the corresponding reagent blank. 
Determination of arsenic in urine and serum 
Arsenic is reported to be present in trace amounts in normal urine and serum 
27(Patty 1963). If a person is affected by arsenic poisoning the amount of 
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arsenic in urine and serum increases. To check the validity of the method 
synthetic samples were prepared by adding known amounts of arsenic to 
serum and urine samples. The samples were deprotonised with 
trichloroacetic acid and filtered. Aliquots were then analyzed for arsenic by 
the proposed and reported methods 29(Pillai,Sunita & Gupta;2000). 
Determination of arsenic in hair and nails 
People drinking arsenic contaminated water have been reported to have 
high arsenic in their hair and nails. About 0.5 to 1.0 g of hair and nail samples 
were placed in a tube containing 10 mL of nitric acid. The tube was closed and 
heated on a hot plate at 100°C for 5 min. After 24 h the lid was opened and 1 
mL of concentrated nitric acid was added and evaporated at 100°C until 1 mL 
of solution remained. Few drops of 10% KI were added to convert As(V) to 
As(III). The presence of any excess of iodine, indicated by light brown colour 
was destroyed by adding few drops of ascorbic acid 28(Sandell 1959). The 
sample was cooled, diluted to 5 mL and analyzed by the proposed and also 
by reported method29(Pillai,Sunita & Gupta;2000). 
Determination of arsenic in plant material 
A sample of plant material (5 g) was digested with 10 mL of HNO3 for 
about 20 min. After cooling, 1 mL of perchloric acid was added and heating 
was continued for about another 10 min. As(V) if any, is reduced to As(III) by 
the process described above. The solution was transferred to a 25 mL 
volumetric flask and diluted to volume with water. Aliquots of the sample 
were analysed by the recommended procedure and also by the reported 
method 29(Pillai,Sunita & Gupta;2000). 
Determination of arsenic in soil 
A known weight (1 g) of a soil sludge sample was placed in a 50 mL beaker 
and extracted 4 times with a 5 mL portion of concentrated HCl. The extract 
was boiled for about 30 min. As(V) if any, is reduced to As(III). The solution 
was cooled and diluted to 25 mL with distilled water. Aliquots of the sample 
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were analysed by the recommended method and also by the reported method 
29(Pillai,Sunita & Gupta;2000).. 
 
Determination of arsenic in natural and polluted water 
Water samples from a river receiving effluent of steel plant and fertilizer 
factory were collected in polyethylene bottles and filtered through Whatman 
41 filter paper. As(V) if any, is reduced to As(III) by the process described. 
Arsenic content was determined directly according to the recommended 
method and also by the reported method 29(Pillai,Sunita & Gupta;2000). 
 
 
 
